Search

Displaying results 3181 - 3190 of 6199 in total
  1. Drug

    Lumefantrine co-artemether

    go.drugbank.com/drugs/DB13085
    ApprovedInvestigationalWithdrawn

    The exact mechanism of action of lumefantrine is not well defined, but it is thought to inhibit -hematin formation, an important detoxification pathway for the parasite. … The combination is an effective and well-tolerated malaria treatment, providing high cure rates even in areas of multi-drug resistance.

  2. Drug

    Delafloxacin

    go.drugbank.com/drugs/DB11943
    ApprovedInvestigational

    Delafloxacin is a fluoroquinolone antibiotic which has been used in trials studying the treatment and basic science of Gonorrhea, Hepatic Impairment, Bacterial Skin Diseases, Skin Structure Infections, and Community Acquired Pneumonia, a...

  3. Drug

    Gabapentin

    go.drugbank.com/drugs/DB00996
    ApprovedInvestigational

    Gabapentin is a structural analogue of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) that was first approved for use in the United States in 1993. It was originally developed as a novel anti-epileptic for the treatment o...

    Products: Ran-gabapentin, Van-gabapentin
  4. Drug

    Anacaulase

    go.drugbank.com/drugs/DB17449
    ApprovedInvestigational

    Therefore, enzymatic alternatives such as anacaulase can lead to better clinical outcomes. … Removing eschar (a process also known as debridement) through surgical procedures can lead to significant trauma, major blood and heat loss and adjacent tissue damage.

  5. Drug

    Diloxanide

    go.drugbank.com/drugs/DB08792
    Experimental

    Although it is not currently approved for use in the United States, it was approved by a CDC study in the treatment of 4,371 cases of Entamoeba histolytica from 1977 to 1990. … Diloxanide (as [Diloxanide furoate]) is an anti-protozoal drug used in the treatment of Entamoeba histolytica and some other protozoal infections.

  6. Drug

    Nemtabrutinib

    go.drugbank.com/drugs/DB18866
    Investigational

    trial NCT05624554 (A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK

  7. Drug

    Omaveloxolone

    go.drugbank.com/drugs/DB12513
    ApprovedInvestigational

    [A257529] In February 2023, omaveloxolone was approved by the FDA for the treatment of Friedreich's ataxia in adults and adolescents aged 16 years and older. … [A257534,A257539] Omaveloxolone acts as an activator of nuclear factor (erythroid-derived 2)-like 2 (Nrf2), a transcription factor that mitigates oxidative stress.

  8. Drug

    Loteprednol etabonate

    go.drugbank.com/drugs/DB14596
    Approved

    As a nasal spray, it can be used for the treatment and management of seasonal allergic rhinitis.

  9. Drug

    Axitinib

    go.drugbank.com/drugs/DB06626
    ApprovedInvestigational

    Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3). … [L6676] Axitinib is an indazole derivative.[A179398] It is most commonly marketed under the name Inlyta® and is available in oral formulations.

  10. Drug

    Tebentafusp

    go.drugbank.com/drugs/DB15283
    ApprovedInvestigational

    to be approved by the FDA. … [A244815] On January 26, 2022, tebentafusp was first approved by the FDA for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma.